“Novartis has decided to invest in various technological and innovative platforms, one of these is that of small-interfering Rna (siRna) for the reduction of LDL cholesterol. Inclisiran is the result of this innovative technology that acts ‘upstream’ of the disease by interfering with the production of those proteins that cause the increase in LDL cholesterol levels. Thanks to this technology, we hope to keep bad cholesterol levels stable and under control in those patients who have a high risk of developing cardiovascular diseases. This also allows a better adherence of patients under treatment with a prolonged containment over time of the risks of cardiovascular diseases “. Like this Valentino Confalone, CEO of Novartis Italiaon the sidelines of the press conference, organized in Rome, by the company to announce AIFA’s ok to the new biological drug inclisiran.
In fact, the decision of the Italian Medicines Agency (Aifa) concerning the reimbursement of the new biological drug inclisiran, capable of halving the levels of ‘bad’ cholesterol, which remains the main cause of cardiovascular diseases in Italy, was published in the Official Journal. they cause 220 thousand victims a year (39% are women, 33% men). “It is very important that the therapy also arrived in Italy – Confalone argues – after being approved in 60 countries around the world because it allows you to keep bad cholesterol levels under control and in a stable manner with high efficacy and tolerability, through only two administrations. year thus facilitating adherence to treatment. Today the innovative mechanism of action of inclisiran is applied to hypercholesterolemia, but we plan to use it in the future also in the treatment of other diseases “.
Hypercholesterolemia is “a subtle pathology” for this reason “Novartis together with the institutions, in particular the Regions, is working to identify those populations with the highest cardiovascular risk with a ‘population medicine’ approach and find prevention solutions, even before treatment, which allow the risk of a cardiovascular event to be removed or excluded ”, concludes the CEO of Novertis Italia.